Skip to main content

Table 2 Cohort characteristics stratified by early oral antimalarial treatment exposure

From: Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study

 

Treated (n = 376, %)

Untreated (n = 48, %)

P-value

Age (years)*

31.2 ± 18.8

23.0 ± 15.9

0.001

Sex

 Female

223 (59.3)

30 (62.5)

0.756

 Male

153 (40.7)

18 (37.5)

Length of Stay (days)†

7, (4, 12)

5, (1, 8)

0.216

Country of Treatment

 Sierra Leone

249 (66.2)

41 (85.4)

0.008

 Liberia

127 (33.8)

7 (14.6)

Rapid diagnostic test for malaria results

 Positive

45 (12.0)

3 (6.3)

0.177

 Negative

167 (44.4)

28 (58.3)

 Not Tested

164 (43.6)

17 (35.4)

Cycle threshold value /viral load

 ≥22 (Low Viral Load)

112 (29.8)

10 (20.8)

0.162

  < 22 (High Viral Load)

135 (35.9)

24 (50.0)

 Missing

129 (34.3)

14 (29.2)

Treatments received first 48 hours of care

 ORS

350 (93.1)

23 (47.9)

0.000

 Cefixime

342 (91.0)

18 (37.5)

0.000

 Multivitamins

243 (64.6)

18 (37.5)

0.000

 Ondansetron

97 (25.8)

14 (29.2)

0.604

 Vitamin C

357 (94.9)

26 (54.2)

0.000

 Zinc Sulphate

19 (5.1)

3 (6.3)

0.727

 Vitamin A

315 (83.8)

15 (31.3)

0.000

Signs & symptoms first 48 hours of care

 Abnormal Bleeding

98 (26.1)

24 (50.0)

0.001

 Coma

2 (0.5)

4 (8.3)

0.002

 Diarrhea

266 (70.7)

32 (66.7)

0.615

 Dysphagia

152 (40.4)

19 (39.6)

1.00

 Dyspnea

117 (31.1)

18 (37.5)

0.753

 Jaundice

22 (5.9)

3 (6.3)

0.754

 Anorexia

252 (67.0)

31 (64.6)

0.747

 Abdominal Pain

237 (63.0)

28 (58.3)

0.530

 Vomiting

223 (59.3)

31 (64.6)

0.534

  1. *Values represent mean with standard deviation
  2. †Values represent median with interquartile range